Press Releases

Date	Title	PDF Version
Jun 03, 2014	Alexion to Present at Investor Conferences
Jun 02, 2014	New Data Presented at the ERA-EDTA Congress Demonstrate Efficacy of Soliris® (eculizumab) in Broad Range of Patients with atypical Hemolytic Uremic Syndrome (aHUS)
Jun 02, 2014	Alexion Initiates Voluntary Nationwide Recall of Certain Lots of Soliris® (eculizumab) Concentrated Solution for Intravenous Infusion Due to the Presence of Visible Particulate Matter in a Single Lot
May 05, 2014	New Data Detailing the Devastating Nature of Hypophosphatasia (HPP) and Treatment Effect of Asfotase Alfa in Infants, Young Children and Juveniles with HPP Presented at the Pediatric Academic Societies Meeting
May 05, 2014	FDA Approves Conversion of Soliris® (eculizumab) Accelerated Approval in aHUS to Regular Approval for the Treatment of Patients with aHUS
May 01, 2014	Alexion to Present at Investor Conferences
Apr 24, 2014	Alexion Reports First Quarter 2014 Results
Apr 24, 2014	Alexion Initiates Multinational Registration Trials of Eculizumab as a Potential Treatment for Patients with Relapsing Neuromyelitis Optica (NMO) and Refractory Generalized Myasthenia Gravis (MG)
Apr 23, 2014	European Commission Grants Orphan Drug Designation to Soliris® (Eculizumab) for the Prevention of Graft Rejection Following Solid Organ Transplantation
Apr 17, 2014	Alexion Announces the Appointment of John T. Mollen to Its Board of Directors

Search